NCT02784171 Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma Status COMPLETED Phase PHASE2/PHASE3
NCT02783300 An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma Status COMPLETED Phase PHASE1
NCT02779751 A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT02779101 Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL) Status UNKNOWN Phase PHASE2
NCT02778685 Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02777385 Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer Status COMPLETED Phase PHASE2
NCT02775851 Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02775812 Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma Status COMPLETED Phase PHASE1
NCT02775435 A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) Status COMPLETED Phase PHASE3
NCT02771197 Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant Status COMPLETED Phase PHASE2
NCT02769520 Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02768701 Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer Status COMPLETED Phase PHASE2
NCT02767934 Pembrolizumab in Treating Minimal Residual Disease in Patients With Acute Lymphoblastic Leukemia Status TERMINATED Phase PHASE2
NCT02766582 Phase II: Pembrolizumab/Carboplatin/Taxol in Epithelial Ovary Cancer Status COMPLETED Phase PHASE2
NCT02759575 A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma Status COMPLETED Phase PHASE1/PHASE2
NCT02758587 Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1) Status UNKNOWN Phase PHASE1/PHASE2
NCT02757391 CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors Status TERMINATED Phase PHASE1
NCT02755272 A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02752685 Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02748564 Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma Status TERMINATED Phase PHASE2